NCT07113587View on ClinicalTrials.gov

Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 8, 2014

Primary Completion Date

July 7, 2017

Study Completion Date

July 7, 2017

Conditions
Peritoneal Dialysis-associated PeritonitisPeritoneal Dialysis (PD)PharmacokineticsIntravenous AdministrationIntravenousMeropenemIntraperitonealAmpicillinAztreonamCiprofloxacinMinimum Inhibitory Concentration (MIC)
Interventions
DRUG

Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis

DRUG

Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis

DRUG

Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis

DRUG

Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis

Trial Locations (1)

A-3100

UK St. Pölten, Sankt Pölten

All Listed Sponsors
collaborator

Karl Landsteiner University of Health Sciences

OTHER

collaborator

University of Vienna

OTHER

collaborator

Medical University of Cologne

OTHER

lead

Karl Landsteiner Insitute for Nephrology and Haemato-Oncology

NETWORK

NCT07113587 - Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis | Biotech Hunter | Biotech Hunter